文献速递白血病

Blinatumomab巩固与维持治疗在复发/难治性B前体急性淋巴细胞白血病成人患者中的应用

Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

本文报告了复发/难治性B前体急性淋巴细胞白血病成人患者接受Blinatumomab诱导后继续巩固和维持治疗的疗效与安全性。在267例接受诱导的患者中,86例(32%)进入巩固,36例(13%)进入维持。维持组较未维持组显示更长总生存,且维持期不良事件发生率较低。

要点

  • Blinatumomab诱导后达到骨髓缓解或完全缓解的患者可继续巩固和维持治疗。
  • 维持组中位总生存未达到,未维持组为15.5个月(95%CI未报告)。
  • 维持期不良事件发生率72.2%,低于诱导期97.2%和巩固期86.1%。

核心结论

  • Blinatumomab诱导后达到缓解的复发/难治性B前体急性淋巴细胞白血病成人患者,继续治疗较早期停药有更长生存。

研究设计与样本

  • 3期临床研究的事后分析,纳入267例接受Blinatumomab诱导的重度经治复发/难治性B前体急性淋巴细胞白血病成人患者。

主要发现

  • 267例接受诱导的患者中,86例(32%)进入巩固(第3-5周期),36例(13%)进入维持(第6周期及以上)。
  • 维持组中位总生存未达到,未维持组为15.5个月(95%CI未报告)。
  • 维持组中位无复发生存为14.5个月(95%CI 7.1-21.9),未维持组为9.8个月(95%CI 8.5-11.1)。
  • 维持期不良事件发生率为72.2%,诱导期为97.2%,巩固期为86.1%。

临床怎么用

  • 对于Blinatumomab诱导后达到骨髓缓解或完全缓解的复发/难治性B前体急性淋巴细胞白血病成人患者,可考虑继续巩固和维持治疗。

局限性

  • 原文未报告维持组与未维持组比较的统计学显著性检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In a phase 3 clinical study of heavily pretreated adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL), overall survival (OS) following blinatumomab, a BiTE (bispecific T-cell engager) immunooncology therapy, was significantly improved vs chemotherapy following induction (cycles 1 to 2). Here we report the efficacy and safety of those who received additional cycles of blinatumomab. Blinatumomab was administered as a continuous IV infusion for 4 weeks in a 6-week cycle. Patients who achieved a bone marrow response (≤5% blasts) or complete remission (full, partial, or incomplete hematological recovery) during induction could receive additional cycles of blinatumomab. OS and relapse-free survival (RFS) for consolidation (cycles 3 to 5) vs no consolidation, and maintenance (cycles ≥6) vs no maintenance were analyzed using Simon-Makuch and Mantel-Byar odds ratios. Of 267 patients who received blinatumomab induction, 86 (32%) entered consolidation and 36 (13%) entered maintenance. Evidence of longer OS was demonstrated among the maintenance group compared with no-maintenance (median OS [95% confidence interval, CI]: not reached for maintenance vs 15.5 months for no maintenance). Median RFS (months; 95% CI) was numerically longer among maintenance group (14.5; 7.1 to 21.9) compared with no-maintenance (9.8; 8.5 to 11.1). A lower incidence of adverse events was seen during maintenance (72.2%) compared with induction (97.2%) and consolidation (86.1%). Adults with R/R ALL who achieved remission following blinatumomab induction had longer survival on continuation therapy than those who discontinued blinatumomab early, supporting the use of blinatumomab as long-term therapy. No new safety signals were reported. This trial was registered at www.clinicaltrials.gov as #NCT02013167.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rambaldi A, Huguet F, Zak P, et al. Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 32289160. doi:10.1182/bloodadvances.2019000874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。